GlaxoSmithKline today announced overall survival (OS) results from COMBI-d which demonstrate a statistically significant reduction in the risk of death for the combination of dabrafenib (Tafinlar™) and trametinib (Mekinist™) compared to dabrafenib monotherapy in patients with BRAF V600E/K mutation-positive metastatic melanoma.

READ FULL ARTICLE Curated publisher From Gsk